07 February 2025
07 February 2025
Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
The assay is developed using the Acrivon Predictive Precision Proteomics platform.
CereVasc’s eShunt System for NPH treatment was efficacious in 97% of patients with no SAEs reported.
The imaging agent is engineered to specifically target the VEGFR2.
Initially launching in Germany, the app will soon be available in the UK, Australia, Canada, and other markets.
The Australian Stroke Alliance supports the trial as principal study partner.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
